Catalina Antonia de Jesús Opazo Hurtado

Catalina Antonia de Jesús Opazo Hurtado

Auto-generated profile, based on publicly available information

Catalina Antonia de Jesús Opazo Hurtado


Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
MQMiguel Horacio Quijano
Miguel Horacio Quijano
SUStalin Omar Toapanta Usuay
Stalin Omar Toapanta Usuay
VCValentina López Corredor
Valentina López Corredor
CMCiro Ernesto Redondo Mendoza
Ciro Ernesto Redondo Mendoza
EPEsteban Fernando Torres Perez
Esteban Fernando Torres Perez
MTMaria Alejandra Cogollo Tarazona
Maria Alejandra Cogollo Tarazona
Emerging synthetic drugs and new psychoactive substances represent a growing challenge for emergency medicine, clinical toxicology, and psychiatry due to their rapidly changing composition, variable potency, frequent polysubstance exposure, and capacity to produce overlapping toxicological syndromes. This study analyzed the clinical presentation, emergency stabilization strategies, and neuropsychiatric complications associated with synthetic cannabinoids, synthetic cathinones, nitazenes, designer benzodiazepines, xylazine, and other emerging psychoactive compounds. A structured analytical review based on the Scientific Method was conducted using recent clinical studies, systematic reviews, toxicological reports, and emergency medicine publications. The evidence showed that these substances can produce neurological, cardiovascular, respiratory, metabolic, and psychiatric abnormalities ranging from agitation, hallucinations, paranoia, and psychosis to seizures, hyperthermia, respiratory depression, bradycardia, hypotension, altered consciousness, and multiorgan complications. Synthetic cannabinoids and synthetic cathinones were prominently represented among psychiatric intoxication cases, while nitazene poisoning demonstrated variable naloxone requirements, including the need for prolonged infusion in selected patients. Xylazine exposure was mainly associated with central nervous system depression, bradycardia, hypotension, and respiratory compromise, particularly in the context of polysubstance use. The findings support a syndromic and physiology-first approach in which airway protection, ventilatory support, cardiovascular monitoring, temperature control, seizure management, treatment of severe agitation, correction of metabolic abnormalities, and selective antidotal therapy are prioritized according to the patient’s clinical condition. Persistent neuropsychiatric manifestations require reassessment after acute stabilization to differentiate transient intoxication from prolonged substance-induced psychiatric syndromes. An integrated approach involving emergency medicine, clinical toxicology, and psychiatry is essential for the effective management of these rapidly evolving intoxications.

30 June 2026 in IECCMEXICO
Verified
Journal Article
Open access
PDF file
Robinson Alexander Morey ContrerasRobinson Alexander Morey Contreras
Robinson Alexander Morey Contreras
GJGary Bastian Medina Jimenez
Gary Bastian Medina Jimenez
ALAndres Mauricio Jaimes Lázaro
Andres Mauricio Jaimes Lázaro
JMJesús Ricardo Martínez Mota
Jesús Ricardo Martínez Mota
CHCatalina Antonia de Jesús Opazo Hurtado
Catalina Antonia de Jesús Opazo Hurtado
VCValentina López Corredor
Valentina López Corredor
Neuropsychiatric manifestations associated with medical diseases represent a major diagnostic challenge because cognitive, behavioral, affective, psychotic, and consciousness-related symptoms may closely resemble primary psychiatric disorders. This review aimed to analyze the principal medical conditions associated with neuropsychiatric manifestations, identify clinical warning signs that suggest a secondary medical origin, evaluate the diagnostic tools used for differential diagnosis, and examine the role of interdisciplinary management. A descriptive and analytical integrative review was conducted using the Scientific Method as the methodological framework. Twenty scientific publications addressing neurological, autoimmune, endocrine, metabolic, nutritional, infectious, and systemic conditions were analyzed. The most frequently represented etiological group was autoimmune/neurological disorders (40%), followed by endocrine diseases (20%), metabolic/nutritional conditions (15%), other general medical conditions (15%), systemic autoimmune diseases (5%), and infectious conditions (5%). Cognitive impairment was the most frequently identified neuropsychiatric manifestation (75%), followed by behavioral changes (70%), psychosis (65%), mood disturbances (60%), and altered consciousness or delirium (50%). The main clinical red flags were acute or subacute onset (60%), neurological abnormalities (55%), altered consciousness (50%), seizures (45%), and rapid cognitive decline (45%). Laboratory studies and neuroimaging were the most frequently represented diagnostic tools, while neurology, psychiatry, and internal medicine showed the greatest interdisciplinary participation. These findings indicate that the differential diagnosis of neuropsychiatric symptoms should not rely exclusively on psychiatric phenomenology. A structured approach integrating temporal evolution, neurological and systemic warning signs, targeted complementary testing, and interdisciplinary evaluation may improve the recognition of potentially reversible medical causes, facilitate appropriate treatment, and reduce diagnostic delay.
1

30 June 2026 in International Science Journal
Verified
Journal Article
Open access
PDF file
JSJuan José Vergara Serpa
Juan José Vergara Serpa
CJCatalina Antonia de Jesús
Catalina Antonia de Jesús
ADAnabel Stephanny Ortiz Dávila
Anabel Stephanny Ortiz Dávila
CMCiro Ernesto Redondo Mendoza
Ciro Ernesto Redondo Mendoza
MVMaría José Muñoz Vinueza
María José Muñoz Vinueza
LHLuis Alberto Erosa-De Haro
Luis Alberto Erosa-De Haro
Major depressive disorder is a heterogeneous psychiatric condition frequently accompanied by persistent cognitive dysfunction involving executive function, attention, memory, processing speed, and motivational processes. Increasing evidence suggests that chronic low-grade inflammation and immunometabolic dysregulation may contribute to these alterations in a biologically distinct subgroup of patients. This study analyzed the relationship between systemic inflammatory activity, metabolic abnormalities, and cognitive impairment in depression through an integrative review based on the scientific method. Evidence from clinical studies, cohort investigations, systematic reviews, meta-analyses, and translational research was examined, with particular attention to C-reactive protein, interleukin-6, tumor necrosis factor-alpha, metabolic syndrome, insulin resistance, oxidative stress, dopaminergic dysfunction, and the tryptophan–kynurenine pathway. The results showed that elevated inflammatory activity is present in a substantial but non-universal proportion of patients with depression and is associated particularly with poorer executive functioning. The coexistence of depression and higher C-reactive protein was related to additional executive impairment, while the interaction between metabolic syndrome and inflammatory/oxidative dysregulation was associated with poorer global cognitive performance. Immune activation was also accompanied by increased kynurenine, reduced tryptophan, an elevated kynurenine-to-tryptophan ratio, and greater depressive symptom burden. Anti-inflammatory interventions showed modest improvements in depressive symptoms and anhedonia among individuals with elevated inflammatory activity, although direct evidence of cognitive improvement remains limited. Overall, the findings support an immunometabolic model in which inflammation interacts with metabolic and neurochemical abnormalities to influence cognitive vulnerability in selected patients with depression. Integrating inflammatory biomarkers, metabolic status, psychiatric assessment, and cognitive evaluation may contribute to more precise clinical stratification and guide future personalized therapeutic strategies.